Genetic Diversity and Characteristics of Drug Resistance Among Treatment-Naive People Living with HIV in Xi’an, China

References

• UNAIDS. Global HIV & AIDS statistics — fact sheet; 2021. Available from: https://www.unaids.org/en/resources/fact-sheet. Accessed January 1, 2022.
   Google Scholar
• Cao W, Hsieh E, Li T. Optimizing treatment for adults with HIV/AIDS in China: successes over two decades and remaining challenges. Curr HIV/AIDS Rep. 2020;17(1):26–34. doi:10.1007/s11904-019-00478-x
   PubMed Web of Science ®Google Scholar
• Zhang FJ, Pan J, Yu L, Wen Y, Zhao Y. Current progress of China’s free ART program. Cell Res. 2005;15(11–12):877–882. doi:10.1038/sj.cr.7290362
   PubMed Web of Science ®Google Scholar
• Phillips AN, Stover J, Cambiano V, et al. Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa. J Infect Dis. 2017;215(9):1362–1365. doi:10.1093/infdis/jix089
   PubMed Web of Science ®Google Scholar
• Gupta S, Neogi U. Following the path: increasing trends of HIV-1 drug resistance in China. EClinicalMedicine. 2020;18:100251. doi:10.1016/j.eclinm.2019.100251
   PubMedGoogle Scholar
• Bertagnolio S, Beanland RL, Jordan MR, Doherty M, Hirnschall G. The World Health Organization’s response to emerging human immunodeficiency virus drug resistance and a call for global action. J Infect Dis. 2017;216(suppl_9):S801–S804. doi:10.1093/infdis/jix402
   PubMedGoogle Scholar
• Kang RH, Liang SJ, Ma YL, et al. Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017. Infect Dis Poverty. 2020;9(1):54. doi:10.1186/s40249-020-00668-5
   PubMed Web of Science ®Google Scholar
• Song YX, Xin RL, Li ZC, et al. Prevalence of transmitted drug resistance among HIV-1 treatment-naive patients in Beijing. Epidemiol Infect. 2018;146(3):339–344. doi:10.1017/S0950268817003016
   PubMed Web of Science ®Google Scholar
• Gao L, Xia H, Zeng R, et al. Pre-treatment and acquired antiretroviral drug resistance among people living with HIV in Tianjin, China. HIV Med. 2022;23(Suppl 1):84–94. doi:10.1111/hiv.13252
   PubMedGoogle Scholar
• Wang Z, Zhang M, Zhang R, et al. Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China. BMC Infect Dis. 2019;19(1):313. doi:10.1186/s12879-019-3927-1
   PubMedGoogle Scholar
• Chang W, Zhang M, Ren Q, et al. HIV-1 genetic diversity and recombinant forms among men who have sex with men at a sentinel surveillance site in Xi’an City, China. Infect Genet Evol. 2020;81:104257. doi:10.1016/j.meegid.2020.104257
   PubMed Web of Science ®Google Scholar
• Zeng R, Ren D, Gong X, et al. HIV-1 genetic diversity and high prevalence of pretreatment drug resistance in Tianjin, China. AIDS Res Hum Retroviruses. 2020;36(10):852–861. doi:10.1089/aid.2020.0056
   PubMed Web of Science ®Google Scholar
• de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005;21(19):3797–3800. doi:10.1093/bioinformatics/bti607
   PubMed Web of Science ®Google Scholar
• Siepel AC, Halpern AL, Macken C, Korber BT. A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res Hum Retroviruses. 1995;11(11):1413–1416. doi:10.1089/aid.1995.11.1413
   PubMed Web of Science ®Google Scholar
• Yuan H, Liu Z, Wu X, et al. Evolutionary characteristics and genetic transmission patterns of predominant HIV-1 subtypes among men who have sex with men in China. Int J Infect Dis. 2020;90:125–131. doi:10.1016/j.ijid.2019.10.035
   PubMed Web of Science ®Google Scholar
• Zhang D, Zheng C, Li H, et al. Molecular surveillance of HIV-1 newly diagnosed infections in Shenzhen, China from 2011 to 2018. J Infect. 2021;83(1):76–83. doi:10.1016/j.jinf.2021.04.021
   PubMed Web of Science ®Google Scholar
• Gan M, Zheng S, Hao J, et al. Spatiotemporal patterns of CRF07_BC in China: a population-based study of the HIV strain with the highest infection rates. Front Immunol. 2022;13:824178. doi:10.3389/fimmu.2022.824178
   PubMed Web of Science ®Google Scholar
• Li X, Li Y, Liu H, Trovao NS, Foley BT. The emergence and transmission dynamics of HIV-1 CRF07_BC in Mainland China. Virus Evol. 2022;8(1):veac014. doi:10.1093/ve/veac014
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines on the public health response to pretreatment HIV drug resistance; 2017. Available from: https://www.who.int/hiv/topics/drugresistance/en/. Accessed December 1, 2020.
   Google Scholar
• Melikian GL, Rhee SY, Varghese V, et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother. 2014;69(1):12–20. doi:10.1093/jac/dkt316
   PubMed Web of Science ®Google Scholar
• Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Oka S. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine. Antimicrob Agents Chemother. 2010;54(4):1596–1602. doi:10.1128/AAC.01480-09
   PubMed Web of Science ®Google Scholar
• Liu Y, Li H, Wang X, et al. Natural presence of V179E and rising prevalence of E138G in HIV-1 reverse transcriptase in CRF55_01B viruses. Infect Genet Evol. 2020;77:104098. doi:10.1016/j.meegid.2019.104098
   PubMed Web of Science ®Google Scholar
• Wei L, Li H, Lv X, et al. Impact of HIV-1 CRF55_01B infection on the evolution of CD4 count and plasma HIV RNA load in men who have sex with men prior to antiretroviral therapy. Retrovirology. 2021;18(1):22. doi:10.1186/s12977-021-00567-z
   PubMed Web of Science ®Google Scholar
• Gan M, Zheng S, Hao J, et al. The prevalence of CRF55_01B among HIV-1 strain and its connection with traffic development in China. Emerg Microbes Infect. 2021;10(1):256–265. doi:10.1080/22221751.2021.1884004
   PubMed Web of Science ®Google Scholar
• Shu Z, Chen Y, Abudureyimu A, et al. Surveillance of HIV-1 drug resistance in Xinjiang: high prevalence of K103N in treatment-naive individuals. Arch Virol. 2018;163(8):2111–2119. doi:10.1007/s00705-018-3825-7
   PubMed Web of Science ®Google Scholar
• Wertheim JO, Oster AM, Johnson JA, et al. Transmission fitness of drug-resistant HIV revealed in a surveillance system transmission network. Virus Evol. 2017;3(1):vex008. doi:10.1093/ve/vex008
   PubMed Web of Science ®Google Scholar
• Kantor R, Smeaton L, Vardhanabhuti S, et al. Pretreatment HIV drug resistance and HIV-1 subtype C are independently associated with virologic failure: results from the multinational PEARLS (ACTG A5175) clinical trial. Clin Infect Dis. 2015;60(10):1541–1549. doi:10.1093/cid/civ102
   PubMed Web of Science ®Google Scholar
• Boender TS, Hoenderboom BM, Sigaloff KC, et al. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa. Clin Infect Dis. 2015;61(11):1749–1758. doi:10.1093/cid/civ656
   PubMed Web of Science ®Google Scholar
• Hermans LE, Hofstra LM, Schuurman R, et al. HIV-1 pretreatment drug resistance negatively impacts outcomes of first-line antiretroviral treatment - week 96 results from the ITREMA trial. AIDS. 2022;36:923–931. doi:10.1097/QAD.0000000000003182
   PubMed Web of Science ®Google Scholar